Monensin, virginiamycin, and flavomycin in a no-roughage finishing diet fed to zebu cattle 1

• Published in: Journal of animal science 2016-10, Vol.94 (10), p.4307
• Main Authors: Lemos, B J M, Castro, F G F, Santos, L S, Mendonça, B P C, Couto, V R M, Fernandes, J J R
• Format: Article
• Language: English
• Subjects: Cattle; Corn; Diet; Feeds
• ISSN: 0021-8812; 1525-3163
• DOI: 10.2527/jas2016-0504

Two experiments were designed to evaluate the effects of monensin, virginiamycin, and flavomycin on growth performance, carcass characteristics, apparent total tract nutrient digestibility, and rumen fermentation of zebu cattle fed a no-roughage finishing diet (whole shelled corn [WSC] based). In Exp. 1, 100 crossbred bulls (Bos indicus ... B. indicus; 392 kg [SD 46.8] average initial BW) were blocked by initial BW in a 101-d feedlot trial. Five treatments were evaluated using 4 pens per treatment (5 bulls/ pen): monensin at 30 mg/kg DM, virginiamycin at 25 mg/kg DM, monensin at 20 mg/kg DM plus virginiamycin at 25 mg/kg DM, flavomycin at 4.4 mg/ kg DM, and monensin at 20 mg/kg DM plus flavomycin at 2.2 mg/kg DM. There were no differences in growth performance (final BW, ADG, DMI, and G:F; P ≥ 0.527) and carcass characteristics (HCW, dressing percent, and 12th-rib fat; P ≥ 0.235) among treatments. In Exp. 2, 7 ruminally fistulated steers were used in a 7 ... 7 Latin square design to evaluate the 5 treatments of Exp. 1 and 2 additional treatments: monensin at 30 mg/kg DM plus virginiamycin at 25 mg/kg DM and monensin at 20 mg/kg DM plus flavomycin at 4.4 mg/kg DM. Experimental periods were 14 d in length (9 d of adaptation and 5 d of measurements). Apparent total tract DM, OM, CP, and NDF digestibilities were similar among treatments (P ≥ 0.224). There was no treatment effect (P ≥ 0.253) in rumen fermentation responses (ruminal pH, rumen ammonia nitrogen, VFA, and number of protozoa). In conclusion, no evidence of benefits to cattle fed a no-roughage WSC-based diet was found to support the use of monensin combined with virginiamycin or flavomycin in the doses tested herein.